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ABSTRACT 
Background 
 Cancer of the ovary is the fourth most common cause of death which 
is related to cancer in India. This study evaluated the various prognostic 
factors in patients with epithelial ovarian cancer who had undergone either 
neoadjuvant chemotherapy and interval debulking or initial surgery followed 
by adjuvant chemotherapy. Immunohistochemical staining was also done 50 
tumour blocks to evaluate the incidence of LASP-1 expression in normal 
ovarian tissue and tissue of epithelial ovarian cancer and to determine if the 
expression of LASP-1 is of prognostic significance in epithelial ovarian cancer. 
Patients and Results 
 Two hundred and eighty patients presenting with epithelial cancer of 
the between January 2005 and December 2007 were analysed. The median 
duration of follow up for all patients was 2.74 years and 8.2 years for the 
living patients. The five year relapse free survival and overall survival of all 
patients was 36.5% and 31% respectively. Ninety seven patients had 
undergone primary surgery and 183 patients received neoadjuvant 
chemotherapy. Sixty six patients went on to have interval debulking surgery. 
Univariate and multivariate analysis were performed on the dataset using. On 
univariate analysis, age(P=0.012), menopausal status(P=0.047),  
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stage (P<0.0001), CA125 levels at presentation(P<0.001), 
histology(P<0.001), grade(P=0.001), primary treatment(P<0.001), type of 
chemotherapy used (P<0.0001), number of chemotherapy cycles administered 
(<0.0001) and residual bulk(<0.0001) were associated with survival status. 
Patients who underwent primary surgery had a significantly longer overall 
survival in univariate analysis (P<0.001). However this was not statistically 
significant on multivariate analysis. On subgroup analysis, we also found that 
the rate of optimal debulking was better in those patients who underwent 
primary surgery when compared to those who had interval surgery after 
neoadjuvant chemotherapy (HR 2.05, 95% CI 1.09 – 3.8, P =0.024) On 
multivariate analysis of all the variables, only stage, CA125 levels at 
presentation, type of chemotherapy used, number of cycles delivered and 
residual bulk significantly correlated with the survival status. 
 LASP-1 was not expressed in normal ovarian and fallopian tube. 
However, immunohistochemical staining for LASP-1 showed cytoplasmic 
staining of cancer cells 18% of the 50 tumours evaluated. 
Conclusions: Advanced stage, CA125 levels >35 U/ml at presentation, non 
platinum based chemotherapy, lesser than 6 cycles of chemotherapy and 
suboptimal debulking are associated with poorer survival. LASP-1 is 
expressed in epithelial ovarian cancer. Since the percentage of patients 
expressing LASP-1 was only 18% studies which include higher number of 
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patients with LASP -1 expression will have to be undertaken to accurately 
correlate LASP-1 expression and survival.  
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